Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Getafe – page 221

3 191 clinical trials in Getafe, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Getafe at a glance
3 191
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 191 trials in Getafe

Open in trial search

Retinitis pigmentosa

Not recruiting

Long-Term Safety and Efficacy Study of Botaretigene Sparoparvovec for Patients with X-Linked Retinitis Pigmentosa

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Cefazolin Sodium
  • Sponsor:Meiragtx Ocular UK Limited

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hormone-dependent prostate cancer

Not recruiting

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study of MDNA11 Alone or with Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MDNA11
  • Sponsor:Medicenna Therapeutics Inc.

Eosinophilic oesophagitis

Not recruiting

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Breast cancer stage IV

Not recruiting

Study of Eftilagimod Alpha and Paclitaxel in Patients with HER2-Negative/Low Metastatic Breast Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Non-small cell lung cancer

Not recruiting

Study of datopotamab deruxtecan combined with immunotherapy and carboplatin in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Epstein-Barr virus associated lymphoma

Not recruiting

Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ganciclovir Sodium
  • Sponsor:Viracta Therapeutics Inc.

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Non-small cell lung cancer

Not recruiting

Study on Livmoniplimab and Budigalimab with Chemotherapy for Adults with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Progressive supranuclear palsy

Not recruiting

Study on the Long-Term Safety of Bepranemab for Adults with Progressive Supranuclear Palsy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bepranemab
  • Sponsor:UCB Biopharma

HER2 positive breast cancer

Not recruiting

Study of Ipatasertib with Trastuzumab and Pertuzumab for Patients with Advanced HER2-Positive Breast Cancer and PIK3CA Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipatasertib
  • Sponsor:Solti Group

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Getafe

What the registry says about research in the country

01 Respiratory & Infectious Diseases

Groundbreaking research focusing on pneumococcal disease prevention and treatment of acute respiratory distress syndrome, including innovative vaccine development and therapeutic approaches.

  • Pneumococcal Vaccines
  • ARDS Treatment
  • Community-Acquired Pneumonia

Studies aim to enhance protection against respiratory infections and improve patient outcomes in severe cases.

02 Neurological Disorders

Innovative clinical trials exploring treatments for multiple sclerosis and Menière's disease, focusing on disease modification and symptom management.

  • MS Treatment Comparisons
  • Inner Ear Disorders
  • Neurological Therapeutics

Research aims to improve quality of life and disease management for patients with chronic neurological conditions.

03 Cardiovascular & Renal Studies

Comprehensive research into chronic renal disease, pulmonary embolism, and vascular conditions, evaluating new therapeutic approaches.

  • Renal Disease Management
  • Pulmonary Embolism Treatment
  • Vascular Health

Studies focus on improving outcomes in patients with complex cardiovascular and kidney conditions.

04 Oncology & Specialized Care

Advanced research in prostate cancer treatment and management of vitiligo, exploring innovative therapeutic options.

  • Cancer Treatment
  • Dermatological Conditions
  • Specialized Therapies

Trials aim to develop more effective treatments for both oncological and dermatological conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.